Unichem Laboratories has announced its financial results for the quarter and year ended March 31, 2026. The company reported a consolidated net profit of ₹10.91 crore for the fourth quarter, compared to ₹52.97 crore in the corresponding period of the previous year. Revenue from operations for the quarter stood at ₹575.12 crore, while total income was ₹598.59 crore. EBITDA for the quarter declined to ₹34.90 crore from ₹83.70 crore in the same period last year, with the EBITDA margin contracting to 6.07% from 14.25% year-on-year.

For the full year ended March 31, 2026, the company posted a net profit of ₹252.84 crore, an increase from ₹137.52 crore in the previous year. Revenue from operations for the fiscal year rose to ₹2,201.85 crore from ₹2,110.97 crore in the prior year. The board has approved the audited financial statements for the year.

Consolidated Financial Performance

The company's financial performance for the quarter and year reflects the impact of exceptional items and operational adjustments. Key metrics from the consolidated results are presented below:

The quarterly EBITDA performance highlights a significant year-on-year compression in operating profitability, as summarised below:

Exceptional items for the year included an employee benefit expense of ₹15.40 crore due to the implementation of new labour codes and interest on a European commission fine of ₹58.26 crore. Additionally, the company recognized a net gain of ₹1.99 crore from the sale of its subsidiary, Unichem Laboratories Ireland, which ceased to be a subsidiary effective April 30, 2025.

Board Decisions and Appointments

The Board of Directors, in its meeting held on May 22, 2026, approved several key resolutions. Mr. Pabitrakumar Bhattacharyya was redesignated from 'Managing Director' to 'Managing Director & Chief Executive Officer' effective immediately. Furthermore, the board approved his re-appointment as Managing Director and Chief Executive Officer for a further period of three years from August 10, 2026, to August 9, 2029, subject to shareholder approval.

The board also re-appointed M/s. Kishore Bhatia & Associates as Cost Auditors and M/s. Ram Agarwal & Associates as Internal Auditors for the financial year 2026-27. The statutory auditors, M/s. N. A. Shah Associates LLP, have issued an unmodified opinion on the annual audited financial results for both standalone and consolidated entities.

Unichem Laboratories Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Friday, May 22, 2026. The intimation was filed on May 6, 2026, in compliance with Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to consider and approve the financial results for the quarter and full year ended March 31, 2026. The agenda covers both standalone and consolidated financial statements, as detailed below:

Regulatory Compliance

The intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited, fulfilling the company's disclosure obligations under applicable SEBI regulations. The filing was signed by Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories Limited.